WebJan 4, 2024 · This includes randomized trials in metastatic NSCLC (SKYSCRAPER-01 and SKYSCRAPER-06) and small cell lung cancer (SKYSCRAPER-02), as well as exploration of tiragolumab in earlier stages, including stage III NSCLC (SKYSCRAPER-03) and locally advanced esophageal cancer (SKYSCRAPER-07). WebDec 10, 2024 · Since 2024, Roche has initiated five phase III trials evaluating tiragolumab plus Tecentriq in early and metastatic disease in lung (SKYSCRAPER-01, SKYSCRAPER …
2024-05-11 OTCQX:RHHBY Press Release Roche Holding AG …
WebMay 11, 2024 · Follows SKYSCRAPER-02 failure In March, Roche said the Phase III SKYSCRAPER-02 study of tiragolumab plus Tecentriq in patients with extensive-stage … WebJan 12, 2024 · First data from Skyscraper-01’s more important endpoint, overall survival, are due in the current quarter. Evercore ISI’s Umer Raffat has suggested that Roche allocated the vast majority of statistical powering in the study to … sharepoint term store examples
Genentech Reports Interim Results for Phase III SKYSCRAPER-01 …
WebMar 29, 2024 · Success in Skyscraper-02 could be harder to come by given the relative intractability of SCLC. However, Merck & Co recently started phase 3 in SCLC with its own Tigit MAb vibostolimab plus Keytruda and chemo, perhaps instilling some confidence in Roche’s strategy. WebJun 5, 2024 · SKYSCRAPER-02 Findings The double-blind SKYSCRAPER-02 trial randomly assigned 490 patients with untreated ES-SCLC to receive four 21-day induction cycles of … WebApr 6, 2024 · On 30 March, Roche published a press release stating that the Phase III pivotal SKYSCRAPER-02 trial of its investigational immunotherapy tiragolumab, in combination with Roche’s FDA-approved programmed cell death protein (PD)-1 inhibitor, Tecentriq (atezolizumab) and carboplatin and etoposide chemotherapy, in 490 patients with … pope farm conservancy